Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Rhea-AI Summary
Nektar Therapeutics (NKTR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, scheduled for May 20, 2025, at the Nasdaq Headquarters in New York City. The company will host a fireside chat that will be webcast starting at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. The presentation will be accessible through a webcast link and on Nektar's investor relations website, with a replay available for 30 days. Interested parties seeking one-on-one meetings with management should contact their H.C. Wainwright representative.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
On the day this news was published, NKTR gained 0.70%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025 – webcast to be available at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-bioconnect-investor-conference-302454157.html
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright BioConnect Conference 2025?
Where can I watch Nektar Therapeutics' (NKTR) H.C. Wainwright conference presentation?
How can investors arrange meetings with Nektar Therapeutics (NKTR) management at the conference?
Where is the H.C. Wainwright BioConnect Conference 2025 being held?
